Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
Stutterheim J, de Lorenzo P, van der Sluis IM, Alten J, Ancliffe P, Attarbaschi A, Aversa L, Boer JM, Biondi A, Brethon B, Diaz P, Cazzaniga G, Escherich G, Ferster A, Kotecha RS, Lausen B, Leung AW, Locatelli F, Silverman L, Stary J, Szczepanski T, van der Velden VHJ, Vora A, Zuna J, Schrappe M, Valsecchi MG, Pieters R.
Stutterheim J, et al. Among authors: escherich g.
Eur J Cancer. 2022 Jan;160:72-79. doi: 10.1016/j.ejca.2021.10.004. Epub 2021 Nov 13.
Eur J Cancer. 2022.
PMID: 34785111
Free article.